Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer.

Neoplasia · 2025 · PMC11617296 · PMID 39561585

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Compared with the control group and the AA-ICB treatment group, the combined treatment group still showed a trend of reduction, although these changes were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.